NCT00312676

Brief Summary

The hypothesis is that the characteristics of extended release Depakote will allow overnight conversion of immediate release to extended release form of Depakote. This has been tested successfully in younger patients but not in individuals over the age of 60. We will include individuals between 60 and 80 years old.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for phase_4

Timeline
Completed

Started Mar 2006

Shorter than P25 for phase_4

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2006

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

April 6, 2006

Completed
4 days until next milestone

First Posted

Study publicly available on registry

April 10, 2006

Completed
6 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2006

Completed
Last Updated

April 10, 2006

Status Verified

March 1, 2006

First QC Date

April 6, 2006

Last Update Submit

April 6, 2006

Conditions

Keywords

TolerabilityDepakote DRDepakote ERElderlyConversion

Outcome Measures

Primary Outcomes (1)

  • Between group comparisons of GI and CNS side effect burden

Secondary Outcomes (2)

  • Between group comparison of Quality of Life as measured bye the QOLIE-89

  • Between group comparison of trough Total and Free valproic acid serum levels

Interventions

Eligibility Criteria

Age60 Years - 90 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • yo and older on stable dose of valproate (Depakote DR)

You may not qualify if:

  • Unstable neurolgical, medical or psychiatric disorder

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Miami VA Medical Center

Miami, Florida, 33125, United States

RECRUITING

MeSH Terms

Conditions

EpilepsyMental Disorders

Condition Hierarchy (Ancestors)

Brain DiseasesCentral Nervous System DiseasesNervous System Diseases

Study Officials

  • R. Eugene Ramsay, MD

    Miami Veterans Administration Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
FED

Study Record Dates

First Submitted

April 6, 2006

First Posted

April 10, 2006

Study Start

March 1, 2006

Study Completion

October 1, 2006

Last Updated

April 10, 2006

Record last verified: 2006-03

Locations